Press Releases Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview Press Releases Events and Presentations Upcoming Events Past Events Presentations Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None20242023202220212020 October 25, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 12, 2021 Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer September 17, 2021 Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 13, 2021 Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition September 7, 2021 Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference August 5, 2021 Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview July 7, 2021 Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference June 10, 2021 Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors May 13, 2021 Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences May 6, 2021 Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview April 23, 2021 Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations April 19, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Next page › Last page » Displaying 37 - 48 of 76 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None20242023202220212020 October 25, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 12, 2021 Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer September 17, 2021 Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit September 13, 2021 Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition September 7, 2021 Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference August 5, 2021 Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview July 7, 2021 Protara Therapeutics to Present at the Ladenburg Thalmann Healthcare Conference June 10, 2021 Protara Therapeutics Announces Appointment of Jane Huang, M.D. to Board of Directors May 13, 2021 Protara Therapeutics to Participate in Upcoming Virtual Investor Conferences May 6, 2021 Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview April 23, 2021 Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations April 19, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Pagination First page « Previous page ‹ Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Next page › Last page » Displaying 37 - 48 of 76
October 25, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 12, 2021 Protara Therapeutics Announces FDA Clearance of Investigational New Drug Application for TARA-002 for the Treatment of Non-Muscle Invasive Bladder Cancer
September 17, 2021 Protara Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
September 13, 2021 Protara Therapeutics Announces Results from a Retrospective Study Evaluating the Prevalence of Cholestasis in Patients Dependent on Parenteral Nutrition
September 7, 2021 Protara Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
August 5, 2021 Protara Therapeutics Announces Second Quarter 2021 Financial Results and Business Overview
May 6, 2021 Protara Therapeutics Announces First Quarter 2021 Financial Results and Business Overview
April 23, 2021 Protara Therapeutics Provides Regulatory Update for TARA-002 for the Treatment of Lymphatic Malformations
April 19, 2021 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
